Rachel Houghton, managing director at Business Moves Group (BMG), explores how pharmaceutical manufacturers can navigate complex regulatory landscapes and safeguard sensitive equipment to ensure seamless international workplace transitions.
Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.
Chris Burton, executive vice president of experiences and design, Sign In Solutions shares six visitor management practices to strengthen compliance culture in pharma.
Nick Petschek, managing director EMEA, Kotter International discusses why the UK Government’s Life Sciences Plan Proves that policy needs change management to succeed.
In the pharmaceutical world, packaging is more than just a container. It is the first guardian of patient safety, product integrity, and regulatory trust. Katia Kayam, LOG Pharma, discusses.
Dr. Subhashis Chakraborty, general manager, head - global product management at ACG Capsules discusses the European Commission's decision on titanium dioxide in pharmaceuticals.
The UK’s new industrial strategy has been welcomed by the Institution of Chemical Engineers (IChemE), though it warns more clarity is needed to ensure lasting benefits. Duncan Lugton, head of Policy & Impact, analyses the plan.
Orbia Fluor & Energy Materials’ pharmaceutical business unit has published a new whitepaper about the industry’s ongoing transition to pressurised metered dose inhalers (pMDIs) to low global warming potential (Low-GWP) propellants.
